Involved site radiation therapy for the treatment of early-stage Hodgkin lymphoma in adolescents and young adults

Portlock, Carol S.

doi:10.2147/coaya.s70370

Cited by 5 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The IMRT can be delivered using HT as previously reported (9). On the other hand, treatment volumes were adapted using "involved-site" (IS) radiotherapy, following the ILROG Guidelines (11).…”

Section: Brief Communicationmentioning

confidence: 99%

Hodkgin lymphoma concomitant of tuberculosis, a therapeutic challenge for multidisciplinary management

Boilève

Kuhnowski

Cassou-Mounat

et al. 2020

Cancer/Radiothérapie

View full text Add to dashboard Cite

Section: Brief Communicationmentioning

confidence: 99%

Hodkgin lymphoma concomitant of tuberculosis, a therapeutic challenge for multidisciplinary management

Boilève

Kuhnowski

Cassou-Mounat

et al. 2020

Cancer/Radiothérapie

View full text Add to dashboard Cite

“…For example, there is currently a major effort to use virtual simulation and CT planning techniques to estimate doses to various parts of the heart for breast cancer RT, and to evaluate the benefits of treatment position (prone vs supine), partial breast irradiation, and deep-inhale breath hold in reducing the mean cardiac volume that receives a significant dose (Gaya and Ashford, 2005; Nieder et al., 2007; Taylor et al., 2007). Increased use of combined modality treatment has allowed reduction of both treatment dose and treated volume in thoracic lymphoma treatments (Portlock, 2015). On the other hand, improved treatment of lower-stage malignancies may improve long-term survival and lead to a greater number of survivors being at risk for late-effect radiation-induced heart disease.…”

Section: Management Of Tissue Reactions In Radiotherapymentioning

confidence: 99%

Radiotherapeutic implications of the updated ICRP thresholds for tissue reactions related to cataracts and circulatory diseases

et al. 2018

View full text Add to dashboard Cite

Radiation therapy of cancer patients involves a trade-off between a sufficient tumour dose for a high probability of local control and dose to organs at risk that is low enough to lead to a clinically acceptable probability of toxicity. The International Commission on Radiological Protection (ICRP) reviewed epidemiological evidence and provided updated estimates of 'practical' threshold doses for tissue injury, as defined at the level of 1% incidence, in ICRP Publication 118. Particular attention was paid to cataracts and circulatory diseases. ICRP recommended nominal absorbed dose threshold for these outcomes as low as 0.5 Gy. Threshold doses for tissue reactions can be reached in some patients during radiation therapy. Modern treatment planning systems do not account for such low doses accurately, and doses to therapy patients from associated imaging procedures are not generally accounted for. While local control is paramount, the observations of ICRP Publication 118 suggest that radiation therapy plans and processes should be examined with particular care. The research needs are discussed in this paper.

show abstract

“…ISRT was adopted, incorporating a prechemotherapy PET, but not requiring it to be in the RT treatment position. Moreover, it utilizes computed tomography (CT) for treatment planning after chemotherapy [10,18]. Most importantly, ISRT is a different concept from IFRT.…”

Section: Introductionmentioning

confidence: 99%

“…ISRT is defined based on prechemotherapy involved nodes/sites, whereas IFRT is defined on anatomical boundaries encompassing the entire lymphatic region. In most situations, these volumes may differ significantly [18,19].…”

Section: Introductionmentioning

confidence: 99%

Long-Term Results of IFRT vs. ISRT in Infradiaphragmal Fields in Aggressive Non-Hodgkins’s Lymphoma Patients—A Single Centre Experience

Galunic Bilic,

Santek,

Mitrovic

et al. 2024

Cancers

View full text Add to dashboard Cite

(1) Background: This study aimed to examine the difference in efficacy and toxicity of involved-field (IFRT) and involved-site radiotherapy (ISRT) fields in infradiaphragmal aggressive non-Hodgkin lymphoma patients. (2) Methods: In total, 140 patients with infradiaphragmal lymphoma treated between 2003 and 2020 were retrospectively evaluated. There were 69 patients (49%) treated with IFRT, and 71 (51%) patients treated with ISRT. The median dose in the IFRT group was 36 Gy, (range 4–50.4 Gy), and in the ISRT group, it was 30 Gy (range 4–48 Gy). (3) Results: The median follow-up in the IFRT group was 133 months (95% CI 109–158), and in the ISRT group, it was 48 months (95% CI 39–57). In the IFRT group, locoregional control was 67%, and in the ISRT group, 73%. The 2- and 5-year overall survival (OS) in the IFRT and ISRT groups were 79% and 69% vs. 80% and 70%, respectively (p = 0.711). The 2- and 5-year event-free survival (EFS) in the IFRT and ISRT groups were 73% and 68% vs. 77% and 70%, respectively (p = 0.575). Acute side effects occurred in 43 (31%) patients, which is more frequent in the IFRT group, 34 (39%) patients, than in the ISRT group, 9 (13%) patients, p > 0.01. Late toxicities occurred more often in the IFRT group of patients, (10/53) 19%, than in the ISRT group of patients, (2/37) 5%, (p = 0.026). (4) Conclusions: By reducing the radiotherapy volume and the doses in the treatment of infradiaphragmatic fields, treatment with significantly fewer acute and long-term side effects is possible. At the same time, efficiency and local disease control are not compromised.

show abstract

Involved site radiation therapy for the treatment of early-stage Hodgkin lymphoma in adolescents and young adults

Cited by 5 publications

References 32 publications

Hodkgin lymphoma concomitant of tuberculosis, a therapeutic challenge for multidisciplinary management

Hodkgin lymphoma concomitant of tuberculosis, a therapeutic challenge for multidisciplinary management

Radiotherapeutic implications of the updated ICRP thresholds for tissue reactions related to cataracts and circulatory diseases

Long-Term Results of IFRT vs. ISRT in Infradiaphragmal Fields in Aggressive Non-Hodgkins’s Lymphoma Patients—A Single Centre Experience

Contact Info

Product

Resources

About